Pharmalittle: We're Reading About Gilead's HIV Drug, FDA Speeding Review of a Rare Disease Drug, and More

Gilead Falls as CVS Hasn’t Yet Added PrEP HIV Shot to Drug Plans

Gilead Sciences Inc.’s shares fell after CVS Health Corp said it hasn’t yet added its new HIV prevention shot to its commercial drug plans.

Pharmalittle: We're reading about Gilead's HIV drug, FDA speeding review of a rare disease drug, and more

Top of the morning to you, and a fine one it is. Despite gray skies hovering over the Pharmalot campus, the air is cool and the surrounding environs are surprisingly quiet, except for the official mascots who are chasing their breakfast. As for us, we are engaged in the usual rituals, starting with firing up the coffee kettle — our choice today is banana split — and foraging for items of interest. On that note, please enjoy the tidbits compiled …

CVS Health Excludes Gilead Sciences’ New HIV Prevention Drug from Commercial Insurance Plans

CVS Health has decided not to include Gilead Sciences&# […] The post CVS Health Excludes Gilead Sciences’ New HIV Prevention Drug from Commercial Insurance Plans first appeared on GeneOnline News. The post CVS Health Excludes Gilead Sciences’ New HIV Prevention Drug from Commercial Insurance Plans appeared first on GeneOnline News.

Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug

Gilead stock toppled Thursday on a report CVS won't add the company's new HIV prevention drug, Yeztugo, to its commercial plans for now. The post Gilead Topples On A Surprise Setback For Its 99.9% Effective HIV Drug appeared first on Investor's Business Daily.